Breast Carcinoma-Associated Antigen, Serum
Use
Aiding in the management of breast cancer in patients with metastatic disease by monitoring the progression or regression of disease in response to treatment. Useful for serial testing in women with prior stage II or III breast cancer who are clinically free of disease. May predict early recurrence of disease in women with treated carcinoma of the breast. Not useful for screening women for or diagnosis of carcinoma of the breast.
Special Instructions
Not provided.
Limitations
Measurement of CA 27.29 is not useful for screening or diagnosis but for monitoring. Normal concentrations do not always rule out disease presence and elevated levels can be observed in nonmalignant conditions. Test has limitations related to heterophilic antibodies interference and requires use with other diagnostic evaluations. Differences in assay methods or kits may lead to variations in results which should not be used interchangeably.
FDA ApprovedNew York Approved
Methodology
Immunoassay (Chemiluminometric)
Biomarkers
Cancer Antigen 27.29 (CA 27.29)
Protein
LOINC Codes
- 17842-6 - Cancer Ag27-29 SerPl-aCnc
- 17842-6 - Cancer Ag27-29 SerPl-aCnc
Result Turnaround Time
1-3 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
0.5 mL
Minimum Volume
0.25 mL
Container
Plastic vial
Collection Instructions
Within 2 hours of collection, centrifuge and aliquot serum into a plastic vial. Specimens that have not been aliquoted will be canceled.
Storage Instructions
Send refrigerated.
Causes for Rejection
Gross hemolysis
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 4 days |
| Refrigerated | 7 days |
| Frozen | 90 days |